Fertility Focus And Norgenix Announce OvuSense™, The Most Accurate Fertility Detector In The Market

SPARTANBURG, S.C., Oct. 23, 2013 /PRNewswire/ -- Fertility Focus and Norgenix Pharmaceuticals, LLC today announced the availability for Fertility Focus's OvuSense™ Fertility Monitoring Device in the United States as well as US territories and military bases.

OvuSense(TM) is the most accurate fertility detector in the market. Developed by Fertility Focus and distributed by Norgenix, this FDA cleared device is an advanced ovulation monitor that delivers an unprecedented 99% sensitivity and 99% accuracy, making it the most precise fertility detector in the market. OvuSense(TM) predicts the onset of ovulation, detects the exact ovulation date just three days after it occurs, and provides all this information in real time on the screen to the user. This performance, for the first time, puts the certainty of ultrasound in a handheld ovulation monitor. (PRNewsFoto/Norgenix Pharmaceuticals, LLC) (PRNewsFoto/NORGENIX PHARMACEUTICALS, LLC)

Norgenix, a wholly owned subsidiary of the J M Smith Corporation, is a North American specialty pharmaceutical, medical device, and biotech company that engages in the development, commercialization, and sales of pharmaceutical products in the women's health arena. Founded in 2008, Norgenix offers quality products that provide solutions to the unmet needs within women's health. With products spanning the continuum of care from pharmaceutical therapies to medical devices, Norgenix is licensed to sell, market, and distribute prescription drug products and medical devices in all 50 United States. (PRNewsFoto/Norgenix Pharmaceuticals, LLC) (PRNewsFoto/NORGENIX PHARMACEUTICALS, LLC)

This FDA cleared device is an advanced ovulation monitor that delivers an unprecedented 99% sensitivity and 99% accuracy, making it the most precise fertility detector in the market. OvuSense™ predicts the onset of ovulation, detects the exact ovulation date just three days after it occurs, and provides all this information in real time on the screen to the user. This performance, for the first time, puts the certainty of ultrasound in a handheld ovulation monitor. Fertility Focus recently presented OvuSense™ at the American Society of Reproductive Medicine (ASRM) Conference in Boston.

Fertility Focus is a British medical company pioneering new technologies for fertility. Norgenix Pharmaceuticals, LLC, a wholly owned subsidiary of the J M Smith Corporation, is a North American distributor with a world-class sales channel for medical device and pharmaceutical products in the women's health arena. Norgenix is licensed to sell, market, and distribute medical devices and prescription drug products in all 50 US states.

"With OvuSense™, we see very positive benefits for clinicians and patients," stated Robert Milnes, CEO of Fertility Focus. "For clinicians, real-time data on the timing of ovulation will enable better patient management and the more efficient use of ultrasound resources. Many patients who enter infertility treatment with 'unexplained infertility' will have a better chance of conceiving more quickly by understanding their cycle properly, and by their early treatment being monitored more closely."

"Our agreement with Norgenix is anticipated to have an immediate and significant impact on our sales expansion efforts as we offer the market an advancement in diagnostic care for an infertile woman," Milnes continued. "The Norgenix team is providing us with multiple ready-made relationships, and we are excited to ramp our production to meet the numerous opportunities Norgenix has presented."

"We are pleased to announce our partnership with Fertility Focus," stated Michael Rackley, COO & Senior Vice President of Norgenix Pharmaceuticals, LLC. "Fertility Focus's OvuSense™ device is an innovative product that perfectly aligns with our strategic mission to offer solutions to unmet needs in women's health. We are very optimistic about the potential for OvuSense™, and we expect to expand the market rapidly."